ABSTRACT
Introduction Alzheimer’s disease (AD) disproportionately affects older adults from marginalized communities. Predictive models using machine learning (ML) techniques have potential to improve early detection and management of AD. However, ML models potentially suffer from biases and may perpetuate or exacerbate existing disparities.
Methods We investigated algorithmic fairness of logistic regression, support vector machines and recurrent neural networks for predicting progression to mild cognitive impairment and AD. Fairness was quantified across gender, ethnicity, and race subgroups using three measures: equal opportunity, equalized odds and demographic parity.
Results All three ML models performed well in aggregate but demonstrated disparate performance across race and ethnicity subgroups. Compared to Non-Hispanic participants, sensitivity for predicting progression to mild cognitive impairment and to AD was 5%-9.6% and 16.8%-24.9% lower, respectively, for Hispanic participants. Sensitivity was similarly lower for Black and Asian participants compared to Non-Hispanic White participants. Models generally satisfied metrics of fairness with respect to gender.
Discussion Although accurate in aggregate, models failed to satisfy fairness metrics. Fairness should be considered in the development and deployment of ML models for AD progression.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Research reported in this publication was supported by the National Institutes of Health under award number R21AG075574.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript